Melissa Baird Sells 58,750 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) COO Melissa Baird sold 58,750 shares of the firm’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $21.04, for a total transaction of $1,236,100.00. Following the sale, the chief operating officer now owns 630,166 shares in the company, valued at approximately $13,258,692.64. This trade represents a 8.53 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Melissa Baird also recently made the following trade(s):

• On Monday, October 7th, Melissa Baird sold 58,750 shares of Hims & Hers Health stock. The shares were sold at an average price of $19.57, for a total value of $1,149,737.50.
• On Wednesday, September 4th, Melissa Baird sold 11,749 shares of Hims & Hers Health stock. The stock was sold at an average price of $14.65, for a total value of $172,122.85.

Hims & Hers Health Price Performance

Hims & Hers Health stock traded up $2.54 during mid-day trading on Tuesday, reaching $23.53. 22,795,206 shares of the company traded hands, compared to its average volume of 9,383,165. Hims & Hers Health, Inc. has a 52-week low of $7.50 and a 52-week high of $30.44. The firm has a market capitalization of $5.14 billion, a price-to-earnings ratio of 53.47 and a beta of 1.06. The firm’s 50 day moving average price is $19.90 and its 200 day moving average price is $18.98.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. During the same period in the prior year, the firm earned ($0.04) earnings per share. Hims & Hers Health’s revenue was up 77.1% on a year-over-year basis. On average, sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Institutional Investors Weigh In On Hims & Hers Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC increased its stake in shares of Hims & Hers Health by 113.1% in the 2nd quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock worth $121,936,000 after acquiring an additional 3,205,108 shares in the last quarter. Farallon Capital Management LLC increased its stake in shares of Hims & Hers Health by 3,890.5% during the first quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock valued at $25,928,000 after purchasing an additional 1,634,000 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Hims & Hers Health by 34.5% in the 3rd quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock worth $63,446,000 after purchasing an additional 883,230 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Hims & Hers Health by 12.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock worth $79,029,000 after buying an additional 482,177 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund grew its stake in shares of Hims & Hers Health by 164.1% in the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 528,142 shares of the company’s stock worth $10,663,000 after acquiring an additional 328,142 shares during the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on HIMS shares. Deutsche Bank Aktiengesellschaft boosted their target price on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, November 6th. Canaccord Genuity Group upped their price objective on shares of Hims & Hers Health from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Bank of America cut shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and decreased their target price for the stock from $32.00 to $18.00 in a research report on Thursday, November 14th. TD Cowen upped their price target on shares of Hims & Hers Health from $25.00 to $28.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Finally, Imperial Capital downgraded Hims & Hers Health from an “outperform” rating to an “in-line” rating in a report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $20.71.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.